Ajanta Pharma gets USFDA inspection report for Paithan manufacturing facility; shares trade flat

Ajanta Pharma was trading flat on Thursday, July 2, after the company received an inspection report for its facility in Maharashtra.

The pharma major in a regulatory filing said that the United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for the company's manufacturing facility at Paithan, Maharashtra.

The inspection has been classified as Voluntary Action Indicated (VAI).

“The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from April 13, 2026, to April 21, 2026,” Ajanta Pharma said.

On April 22, the firm had stated that the US FDA had concluded an inspection at the Paithan facility. The inspection was closed with the issuance of Form 483 with five observations.

Ajanta Pharma Q4 earnings

The drug firm had reported a 18.4% year-on-year (YoY) increase in net profit for the fourth quarter of the quarter ended March 31, 2026, (Q4 FY26) at ₹266.7 crore compared with ₹225.3 crore in the year-ago period.

Its revenue for the quarter jumped 21.5% to ₹1,421.6 crore as against ₹1,170.4 crore in the same quarter of the previous fiscal year.

The earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 12.2% to ₹333.4 crore in the reporting quarter in contrast to ₹297.2 crore in the corresponding period last year. EBITDA margin stood at 23.5% for the quarter, compared with 25.4% in the same period last year.

Ajanta Pharma share price trends

At 3 PM, Ajanta Pharma shares were trading at ₹3,345.4 apiece on the National Stock Exchange, falling 0.06%. The stock had touched an intraday high of ₹3,360 per share and a day's low of ₹3,293.90 apiece during the session.

Shares of the firm have rallied 15% over a month, while they have climbed 14% from the beginning of the year.

Shares of the company had touched their one-year high of ₹3,506.90 apiece on July 1, 2026, while their 52-week low of ₹2,329.90 was hit on September 30, 2025.

As of July 2, 2026, Ajanta Pharma has a market capitalisation of ₹41,828.45 crore, NSE data showed.